Search results
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 2 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance· 3 days agoPfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 3 days agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 2 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks· 5 days agoFree Report) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Pfizer falls in, has ...
Five Questions with Biz-Savvy Alum Georgia Papathomas
Columbia University News· 18 hours agoAs a seasoned executive who has led IT at biopharma giants like Pfizer and Johnson & Johnson,...
Bridgeway Capital Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoBridgeway Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 26.0% during the 4th quarter, according to its most recent 13F filing ...
Pfizer Inc. (NYSE:PFE) Shares Sold by Cresset Asset Management LLC
ETF DAILY NEWS· 3 days agoCresset Asset Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 13.5% in the fourth quarter, according to the company in its most recent disclosure ...
Pfizer Inc. (NYSE:PFE) Shares Sold by Waddell & Associates LLC
ETF DAILY NEWS· 5 days agoWaddell & Associates LLC reduced its position in Pfizer Inc. (NYSE:PFE – Free Report) by 40.0% in the 4th quarter, according to its most recent disclosure with the Securities ...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters via AOL· 3 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...